Encompass Health Corp (EHC) · Oct 28, 2026 · Earnings
Encompass Health earnings beat as 2026 guidance rises
Beat — Adjusted EPS $1.52 vs ~$1.36 consensus; FY adjusted EPS guide raised to $6.23-$6.37
Encompass Health’s Q3 earnings beat expectations and lifted 2026 guidance, while a billing-system disruption raised bad-debt reserves.
Encompass Health is expanding the country’s largest inpatient-rehabilitation network, using de novo hospitals and bed additions to capture growing demand; its stated plan calls for 6–10 new hospitals and 80–120 added beds annually through 2027. This quarter advances that strategy: operating growth accelerated enough to support a guidance increase, although execution around billing collections remains an emerging blemish.
The quarter beat the published benchmark. Adjusted EPS was $1.52 versus a published consensus of roughly $1.36, while revenue of $1.61 billion was modestly above the roughly $1.60 billion estimate. The filing shows the underlying engine was broad: discharges rose 5.7%, same-store discharges grew 3.0%, and revenue per discharge increased 4.0% (Revenue). The company said, “revenue increasing 8.9% and Adjusted EBITDA growing 15.5%,” reinforcing that the result was not merely a tax or accounting-driven beat.
| Metric | Q3 2026 | Q3 2025 | Change / benchmark |
|---|
| Net operating revenue | $1,609.5M | $1,477.5M | +8.9% (Summary results) |
| Adjusted EBITDA | $346.6M | $300.1M | +15.5% (Summary results) |
| Adjusted EPS | $1.52 | $1.23 | +23.6%; ~$1.36 consensus |
| Discharges | 69,605 | 65,839 | +5.7% (Revenue) |
| Same-store discharge growth | 3.0% | — | (Revenue) |
| Adjusted free cash flow | $263.4M | $174.2M | +51.2% (Summary results) |
| FY 2026 revenue guidance | $6.45B–$6.50B | $6.41B–$6.49B prior | Raised (2026 Guidance) |
| FY 2026 adjusted EBITDA guidance | $1.395B–$1.415B | $1.365B–$1.395B prior | Raised (2026 Guidance) |
| FY 2026 adjusted EPS guidance | $6.23–$6.37 | $6.02–$6.25 prior | Raised (2026 Guidance) |
The most important change is the raised full-year outlook. Management lifted the midpoint of adjusted EBITDA guidance by $25 million and the adjusted EPS midpoint by $0.165, not merely reaffirming a strong quarter. The upgrade suggests Q3 operating momentum and reimbursement assumptions more than offset higher expected bad-debt reserves and labor costs. The release explicitly says, “the Company today reported its results of operations for the third quarter ended September 30, 2026,” and presents the revised ranges as updated full-year guidance.
The growth model is still translating into capacity. Encompass Health opened four hospitals totaling 189 beds year to date, added 85 beds to existing hospitals, and plans eight new hospitals totaling 389 beds in 2026. That matters because the beat is accompanied by continued volume expansion rather than relying solely on pricing; however, the company is funding this through substantial capital deployment, with $695 million to $755 million planned for capacity expansion and replacement facilities (Uses of free cash flow).
The main counterweight is collection quality, not demand. Bad-debt reserves rose to 2.7% of revenue from 1.9%, and Medicaid supplemental payments declined $10 million (Revenue). The filing attributes the reserve increase primarily to “a billing and collecting disruption issue following a system conversion in Q2 2026.” That is a real operating execution issue, but the raised outlook indicates management currently views it as contained rather than large enough to derail the year.
Regulatory friction remains a forward business risk, but it did not impair this quarter’s read. Beginning January 1, 2027, 108 hospitals will be subject to CMS’s Review Choice Demonstration, including 75 newly added hospitals under the MAC Jurisdiction JJ expansion; those facilities initially face 100% pre-claim or post-payment review (RCD and TEAM). The exposure is meaningful, but the filing gives no evidence of a current reimbursement shock, and only 2% of 2025 discharges fell within TEAM’s geographic, episode, and payer parameters (RCD and TEAM).
Bottom line: This was a genuine operating beat followed by a credible guidance raise, strengthening the expansion story. The billing disruption and higher bad-debt reserves are the key execution issue to monitor, but they currently look contained relative to the upgraded outlook.
What to watch next
October 29 earnings call and RCD expansion on January 1, 2027
Original filing on SEC EDGAR
More Encompass Health Corp news
